Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients ...

Personalized cancer vaccines are showing real clinical results, with melanoma patients on the mRNA-4157/pembrolizumab ...

Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.

Federal health regulators have formally warned ImmunityBio Inc. for making misleading promotional claims about Anktiva, the company’s bladder cancer drug. Dr. Patrick Soon-Shiong, the company’s ...

ImmunityBio's first-quarter revenue more than tripled year-over-year, powered by the rapid commercial uptake of its bladder cancer immunotherapy ANKTIVA. The company reported preliminary net product ...

When Israeli Defense Minister Israel Katz announced, with the satisfied air of an industrialist surveying demolished ...

ImmunityBio finds itself navigating a stark divergence between its commercial success and a burgeoning legal crisis. While the biotech firm reports record-breaking revenue for its cancer drug Anktiva, ...

Acting Attorney General Todd Blanche signed an order Thursday reclassifying state-licensed marijuana as a less dangerous drug ...

President Trump's move reclassifies medical marijuana as a Schedule III drug. Discover what types of drugs marijuana is now ...

The order signed by Todd Blanche does not legalize marijuana for medical or recreational use under federal law. But it does ...

President Donald Trump’s administration has reclassified medical marijuana , which is already licensed in most states, as a less dangerous drug. The order signed Thursday by the nation’s acting ...

ImmunityBio, Inc. faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, ...